Olivier Van de Steen

Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial

Toby M. Maher, Ellen M. van der Aar, Olivier Van de Steen et al. · The Lancet Respiratory Medicine · 2018 · 232 citations · Full text

Fibrosis, Novel Autotaxin Inhibitor, Allergy +7

CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials

Scott C. Bell, Peter J. Barry, K. De Boeck et al. · Journal of Cystic Fibrosis · 2019 · 52 citations · Full text

GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1)

Jane C. Davies, Olivier Van de Steen, Silke van Koningsbruggen‐Rietschel et al. · Journal of Cystic Fibrosis · 2019 · 27 citations · Full text

Molecular Pharmacology, Medicine, Physiology +3

The Burden of Severe Respiratory Syncytial Virus Disease Among Children Younger than 1 Year in Central and Eastern Europe

Olivier Van de Steen, Farzaneh Miri, Marta Gunjaca et al. · Infectious Diseases and Therapy · 2016 · 16 citations · Full text

GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN)

Silke van Koningsbruggen‐Rietschel, Katja Conrath, Rainald Fischer et al. · Journal of Cystic Fibrosis · 2019 · 16 citations · Full text